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Abstract: There is a lack of valid disease-specific patient-reported outcome measures (PROMs) for 
detecting symptoms and concerns in patients with advanced chronic heart failure (CHF). The Palliative 
care Outcome Scale (POS) and Integrated Palliative care Outcome Scale (IPOS) are specifically developed 
to capture the main symptoms and concerns of people severely affected by advanced disease. The aim 
of this study was to determine whether POS and IPOS captures the main symptoms and concerns self-
reported by patients with advanced CHF. A secondary analysis of existing POS/IPOS data collected in three 
longitudinal studies was conducted. POS and IPOS start with an open-ended question for patients to report 
their main problems and concerns, followed by subsequent closed questions on a range of symptoms and 
other concerns. Descriptive statistics were used to report the results. The 102 participants from the three 
datasets had median age 81 years (SD ±9.84 years); 62% male; 87% white. A total of 107 concerns were 
reported in the first, open POS/IPOS question seeking the patient’s main concerns. Of these, 83 (77%) 
were reflected in the subsequent IPOS/POS closed questions. The high correspondence between the free-
text responses and the closed questions indicates that most issues are captured by the POS/IPOS items. In 
conclusion, the generic versions of POS and IPOS do capture the main problems and concerns of patients 
with advanced CHF. Minor adaptations and further psychometric validation of POS and IPOS are needed in 
this population. 
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Introduction
Chronic heart failure (CHF) remains one of the major 
causes of morbidity and mortality globally (1). As advances 
in treatments have prolonged life, considerably more 
attention needs to be paid to improving quality of life (2). 
CHF has a significant impact on physical, psychological 
and social well-being, and there is substantive literature 
describing symptom distress and unmet needs among 
people with CHF, especially towards the end of life (3).
Patients affected by heart failure experience a gradual 
decline, punctuated by episodes of acute deterioration and 
eventually sudden death or death owing to progressive 
heart failure (4). Generally, three phases of disease can 
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be described: a relatively stable primary phase; then one 
or more secondary phases of decline requiring increased 
utilization of hospital care; and ultimately, a tertiary terminal 
phase of inexorable deterioration (advanced CHF) (4). 
However, it may be difficult to know when the third phase 
is being reached.
The diagnosis of advanced CHF depends on patient’s 
symptoms, prognostic markers, and presence of end-organ 
damage. Advanced CHF encompasses patients who remain 
severely symptomatic despite optimal management (5). 
Patients with advanced CHF frequently experience 
symptoms of breathlessness (6-8), fluid retention (pulmonary 
or systemic congestion) (7), pain (9), and fatigue at rest or 
on minimal exertion (7,10-12), and cardiac cachexia (5). 
A variety of changes in emotional, social and spiritual 
wellbeing are described by this group of patients (13). 
However, these symptoms and other concerns are poorly 
recognised and addressed (14), both because of the 
reluctance to face deterioration and the lack of specialist 
knowledge in this final illness trajectory (15).
The literature identifies a lack of valid disease-specific 
patient-reported outcome measures (PROMs) for detecting 
symptoms and concerns in patients with advanced CHF 
(16,17). There are different questionnaires for CHF with 
good evidence of reliability, validity, responsiveness, and 
feasibility in the CHF population (18). But although the 
Minnesota Living with Heart Failure Questionnaire and 
the Kansas City Cardiomyopathy Questionnaire meet 
these criteria best (11,19,20), no measures have been fully 
validated for the use in far advanced disease (14).
The Palliative care Outcome Scale (POS) and Integrated 
Palliative care Outcome Scale (IPOS) are designed to 
measure those symptoms and concerns most often reported 
by people with advanced illness; physical and psychological 
symptoms, social and spiritual aspects, communication, 
information and practical needs (21). POS and IPOS have 
been developed from interviews with patients experiencing 
advanced illness, and start with an open-ended question 
(‘what have been your main problems or concerns over the 
past week?’) for patients to report their main problems and 
concerns, followed by subsequent closed questions on a 
range of symptoms and other concerns which are important 
to patients in advanced illness (21). POS demonstrates good 
construct validity and test/retest reliability (22). Internal 
consistency is also good (22). IPOS represents a refinement 
of POS to capture more details about symptoms and for this 
reason, it differs from POS in a small number of items (23). 
IPOS is now available for clinical use, and a refined version 
is currently undergoing full validation in the United 
Kingdom (24). Both patient and proxy versions of POS and 
IPOS are available, making it possible to use even when 
someone is very unwell (21). Both questionnaires can be 
used across different settings: home, nursing home, hospital, 
and hospice (21) and are freely  available on a web platform 
www.pos-pal.org for clinical and research use. POS and 
IPOS have been used for patients affected by CHF (21), 
although few studies have been performed to evaluate them 
in advanced CHF (14,25).
This study therefore aims to determine whether POS 
and IPOS captures the main symptoms and concerns self-
reported by patients with advanced CHF.
Methods
Secondary analysis was conducted, using existing data 
collected in three studies in which POS and IPOS were 
used among patients affected by CHF. Two studies were 
identified by reviewing the studies included in two recent 
systematic reviews about the use of POS (23,26). Both 
reviews aimed to appraise the general use of POS in the 
context and nature of its use and identify strengths and 
weaknesses of this patient reported outcome measure 
(23,26). The third study about the use of IPOS in advanced 
CHF (14), was identified by consulting the CHF group 
working at the Cicely Saunders Institute of Palliative Care, 
Policy and Rehabilitation, King’s College London.
The characteristics of the studies are reported in Table 1. 
All the three studies provided longitudinal data, over 
varying lengths of time. For this secondary analysis, only 
the first, baseline questionnaire (POS or IPOS) was used, 
for consistency across studies.
Both quantitative and qualitative analyses were 
undertaken. For the analysis of the first open question of 
the POS and IPOS, thematic analysis was used to search for 
and identify themes (28). Thematic analysis is an approach 
to identify themes that emerge through the analysis of the 
textual data (29). A theme can be defined as a pattern in 
the information that describes and organizes the possible 
observations (30). Themes are not preconceived, but 
emerge from the data (30). The use of this methodology is 
based on the following steps (29,30): reading and re-reading 
the qualitative data, coding this data, developing a coding 
frame, applying the coding frame to all data, re-iterating the 
coding frame to encompass all themes, and then analyzing 
and interpreting these themes.
Descriptive statistics are used to report the answers to 
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the IPOS and POS closed questions. Answers to the open 
question of POS and IPOS (‘what have been your main 
problems or concerns over the past week?’) were then 
compared with the POS/IPOS items. In this way, concerns 
expressed by the participants, but not included in POS/IPOS 
closed questions, could be identified.
To assess the rigor of the coding and cross-check the 
coding and thematic analysis, two researchers (Anna Oriani 
and Amy Gadoud)  analyzed the data independently, 
and then compared. A third impartial researcher (Lesley 
Dunleavy) was consulted in the event of disagreement. 
Missing data was very low (less than 5%), assumed to be at 
random and excluded from the analysis (29).
Ethical concerns
The Research and Innovation Office of King’s College 
Hospital, London and the UK Health Research Authority 
confirmed that additional ethical approval was not needed, 
as this was within the scope of the original ethical approval 
for all three studies. All the three previous studies have been 
approved by each local medical ethics committee and all the 
participants have signed a consent form. 
Results
Data came from 102 participants. Patients’ characteristics 
are reported in Table 2. Mean age was 81 years (SD ±9.84 
years), 62% were male and 87% white. Baseline New 
York Heart Association (NYHA) score was available for 65 
patients: 19 patients were classified NYHA II, 37 patients 
were classified NYHA III, and 9 patients were classified 
NYHA IV.
In total, 88/102 (86%) completed the POS or IPOS 
questionnaire, with 19 patients providing three responses 
to the first open question, 18 providing two, 26 providing 
one and 25 patients providing no concerns. A total of 107 
concerns were reported in the first open question. Of these 
concerns, 83 (77%) were reflected in the subsequent IPOS/
POS closed questions. Most issues raised in the first open 
question were subsequently also captured in the closed 
POS/IPOS items (see Table 3).
In the analysis of the first open question, we identified 
some themes as unique concerns, as for instance concerns 
caused by other co morbidities expressed as “kidney 
infection” or “COPD”. Unique concerns about the poor 
quality of life, loneliness and self-esteem were also reported: 
“I feel very ill”; “Feeling and being sick all the time” or 
“More frustrated”; “Ever decreasing the quality of life” 
or “Have tired enough of life”; “Loss of independence” 
or “Losing touch with people, isolation”. Other themes 
identified as unique concerns included symptoms caused by 
fluid retention, nocturnal breathlessness, itch and cough.
Breathlessness was reported by 14 (16%), especially 
when moving: “Lack of breath when I move”; “Shortness 
of breath when I walk or exert myself”. Seven patients 
(8%) reported anxiety, described as “Feeling anxious all the 
time”. Among patients who reported pain (n=9; 10%), only 
one reported angina as a major concern, writing as having 
been “Frightened when I had angina, and I was on my 
own”. Mobility problems have been described differently 
by patients, such as: “Loss of balance”, “Disappointed by 
travelling limitations” or “Difficulty in walking more than 
50 yards.”
Table 1 Characteristics of the three studies included in the secondary analysis
Study  
characteristics
Dataset I (25) Dataset II (14) Dataset III (27)
Setting Hospice 2 nurse-led CHF clinics 3 renal unit 
Aims To test a novel combined heart 
failure palliative care service 
model
To determine the feasibility and acceptability of 
an intervention that involves the IPOS 
To describe symptoms and other  
concerns of patients with end-stage 
renal disease, managed without dialysis 
over time
Methods Mixed method feasibility study Mixed method feasibility study Longitudinal study
Patients 40 patients with advanced 
chronic heart failure with  
conserved or reduced ejection 
fraction
25 patients affected by CHF, with NYHA  
functional class III or IV. Patient inclusion criteria 
were developed according to the European  
Society of Cardiology’s CHF definition
37 patients with CHF out of a total of 74 
patients with end-stage renal disease 
and who were being managed without 
dialysis
CHF, chronic heart failure; NYHA, New York Heart Association; IPOS, Integrated Palliative care Outcome Scale.
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Table 2 Participants’ characteristics (N=102)
Variables
Numbers and  
percentages
Demographic characteristics
Age Mean: 81 years; 
SD: ±9.84 years
Gender
Male 63 (62%)
Female 39 (38%)
Ethnicity 
White 89 (87%)
Black 6 (6%)
South Asia 3 (3%)
Chinese 1 (1%)
Other 3 (3%)
Co-morbidities
Renal disease 88 (86%)
Ischemic heart disease (including myocardial 
infarction)
61 (60%)
Diabetes mellitus 37 (36%)
Hypertension 14 (14%)
Other (peripheral or central) vascular diseases 25 (25%)
Atrial fibrillation 17 (17%)
Thromboembolism 1 (1%)
Valve defects 7 (7%)
Malignancies 19 (19%)
COPD 15 (15%)
Depression 5 (5%)
Liver disease 1 (1%)
COPD, chronic obstructive pulmonary disease.
Table 3 Symptoms and concerns reported by patients in the first 
open question of POS/IPOS
Symptoms and concerns  
(categorized into themes)
Number of  
patients, N (%)
Poor mobility 21 (24%)
Shortness of breath 14 (16%)
Fatigue 12 (14%)
Pain 9 (10%)
Problems with other medical conditions 9 (10%)
Practical matters related to illness 8 (9%)
Feeling anxious 7 (8%)
Low quality of life 4 (5%)
Fluid retention or edema 4 (5%)
Other symptoms 3 (3%)
Poor appetite 3 (3%)
Loneliness 2 (2%)
Lack of concentration/poor memory 2 (2%)
Concerns about self-esteem 2 (2%)
Bowel-related concerns 1 (1%)
Drowsiness 1 (1%)
Itch 1 (1%)
Cough 1 (1%)
Anxiety of carers/family 1 (1%)
Depression 1 (1%)
Not sleeping well 1 (1%)
Patients had the chance to provide 3 answers to the first open 
IPOS/POS question. Some patients provided 3 answers, some 
2 or 1 and some.
Discussion
This secondary analysis found that the generic versions of 
POS and IPOS capture a high proportion of the symptoms 
and concerns of patients affected by advanced CHF. There 
is a high correspondence between the free-text responses to 
the first open question and the subsequent closed questions 
in POS/IPOS. Only a limited number of additional 
concerns were gathered from the first open question 
of POS/IPOS. Among these unique concerns, patients 
were mostly distressed by co-morbidities, fluid retention, 
nocturnal breathlessness, loneliness, itch, cough, and sleep 
disturbance.
In reference to the POS and IPOS closed questions, 
patients reported breathlessness, fatigue and drowsiness 
as most prevalent.  Pain,  sore and dry mouth and 
gastrointestinal symptoms (nausea, constipation, and poor 
appetite) were also common.
This secondary analysis found that some participants 
reported the same symptom or concern both in the free-text 
answers and in the closed questions. This may be due to 
different reasons, including the desire to emphasize a highly 
burdensome symptom, or to report it as a high priority. The 
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responses to the open-ended question provide reassurance 
that many of the relevant issues are captured by the POS/
IPOS items, highlighting relatively few problems or 
concerns not covered by the closed questions. However, the 
first open question remains important to uncover the main 
concerns which the patient prioritizes, and report these in 
their own words.
We tried to identify all existing POS/IPOS datasets which 
included over 30% of participants with advanced CHF. The 
use of three datasets together is useful; it increases the size of 
the analyzed dataset, and thus the strength of our findings. 
However, this was a secondary analysis of data collected 
to address primary hypotheses that were different from 
our study. The studies were conducted for diverse primary 
aims and some important data were therefore missing. For 
instance, it was not possible to know the NHYA stage for all 
the patients. Moreover, dataset III was collected specifically 
to study the trajectory of symptoms in patients affected by 
end-stage renal failure; a potentially different population 
who may have a higher proportion of co-morbidities. 
However, from this dataset we selected only the patients with 
CHF as a specific co-morbidity. Given that the prevalence 
of the symptoms reported by this patient cohort is similar to 
the ones described in literature (11,31), however, inclusion 
of this dataset was justified.
In conclusion, POS and IPOS assess palliative care 
symptoms and concerns, and are specifically designed as an 
outcome measure for use among people severely affected by 
any chronic disease (32). This analysis of the generic version 
of POS and IPOS in patients affected by advanced CHF, 
showed that these two PROMs comprehensively reflect 
the main problems and concerns of these patients, and the 
open question can capture any remaining unique concerns. 
These findings are consistent with the literature on the 
most prevalent concerns of this secondary analysis cohort 
of patients. Minor adaptations and further psychometric 
validation of POS and IPOS are needed in patients with 
advanced CHF to further determine the value of these 
measures in this population. 
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